Education
About Us
Working with TipRanks
Follow Us
Trevi Therapeutics Inc (TRVI)
NASDAQ:TRVI
TRVI Stock Chart & Stats
$10.19
<$0.01(0.12%)
At close: 4:00 PM EST
$10.19
<$0.01(0.12%)
Day’s Range― - ―
52-Week Range$2.36 - $10.31
Previous CloseN/A
Volume226.18K
Average Volume (3M)2.51M
Market Cap
$1.18B
Enterprise Value$510.02M
Total Cash (Recent Filing)$203.88M
Total Debt (Recent Filing)$891.00K
Price to Earnings (P/E)―
Beta0.08
Next Earnings
Nov 05, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding121,776,855
10 Day Avg. Volume1,694,730
30 Day Avg. Volume2,508,684
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue3.49K
Enterprise Value/Gross Profit-13.42K
Enterprise Value/Ebitda-10.24
Forecast
1Y Price Target
$21.13Price Target Upside107.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentHaduvio has demonstrated impressive placebo-adjusted reductions in cough across multiple clinical studies.
Market OpportunityTrevi's Haduvio is seen as a multi-billion dollar opportunity, addressing significant treatment gaps in chronic cough.
Regulatory OutlookThe upcoming regulatory update is likely to be exciting, with potential clarity on Haduvio's time-to-market being a key factor for investors.
Bears Say
Clinical RisksExploring if Haduvio induced constipation could counterbalance diarrhea in anti-fibrotic treated IPF patients is seen as worth exploring in future trials.
Market CompetitionThe unmet need in chronic cough treatment has caught the interest of major pharma companies, highlighting the potential of Trevi's solution.
Regulatory ChallengesThe ERS update is expected to be incremental in nature, with no significant additional nuance anticipated.
Trevi Therapeutics News
TRVI FAQ
What was Trevi Therapeutics Inc’s price range in the past 12 months?
Trevi Therapeutics Inc lowest stock price was $2.36 and its highest was $10.31 in the past 12 months.
What is Trevi Therapeutics Inc’s market cap?
Trevi Therapeutics Inc’s market cap is $1.18B.
When is Trevi Therapeutics Inc’s upcoming earnings report date?
Trevi Therapeutics Inc’s upcoming earnings report date is Nov 05, 2025 which is in 20 days.
How were Trevi Therapeutics Inc’s earnings last quarter?
Trevi Therapeutics Inc released its earnings results on Aug 07, 2025. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.104 by $0.014.
Is Trevi Therapeutics Inc overvalued?
According to Wall Street analysts Trevi Therapeutics Inc’s price is currently Undervalued.
Does Trevi Therapeutics Inc pay dividends?
Trevi Therapeutics Inc does not currently pay dividends.
What is Trevi Therapeutics Inc’s EPS estimate?
Trevi Therapeutics Inc’s EPS estimate is -0.1.
How many shares outstanding does Trevi Therapeutics Inc have?
Trevi Therapeutics Inc has 121,776,855 shares outstanding.
What happened to Trevi Therapeutics Inc’s price movement after its last earnings report?
Trevi Therapeutics Inc reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.104. Following the earnings report the stock price went up 1.644%.
Which hedge fund is a major shareholder of Trevi Therapeutics Inc?
Currently, no hedge funds are holding shares in TRVI
Trevi Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.13 (107.36% Upside)
$21.13 (107.36% Upside)
Blogger Sentiment
Bullish
TRVI Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 303.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.9%
Last 30 Days ▲ 9.9%
Last 30 Days ▲ 9.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
220.44%
12-Months-Change
Fundamentals
Return on Equity
-35.74%
Trailing 12-Months
Asset Growth
182.26%
Trailing 12-Months
Company Description
Trevi Therapeutics Inc
Trevi Therapeutics (TRVI) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious neurological conditions. The company's lead product candidate, Haduvio, is being developed for the treatment of chronic pruritus (itch), and chronic cough in adults with idiopathic pulmonary fibrosis (IPF). Trevi Therapeutics operates within the biotechnology and pharmaceutical sectors, aiming to address unmet medical needs in these niche markets.
TRVI Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was largely positive, highlighting successful trial results, a strong financial position, and clear plans for future clinical development. While there were increased expenses and a reported net loss, these were balanced by significant achievements and forward-looking strategies.View all TRVI earnings summariesTRVI Stock 12 Month Forecast
Average Price Target
$21.13
▲(107.36% Upside)
Technical Analysis
Nektar Therapeutics
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Praxis Precision Medicines
―
Ownership Overview
11.78% Insiders
8.59% Mutual Funds
61.22% Other Institutional Investors
10.96% Public Companies and
Individual Investors